DexCom's growth rate has been improving, but that hasn't been enough of a reason for investors to buy up the stock.

DexCom's stock narrative has shifted as analysts lower their fair value estimate from $98.40 to $84.96, marking a significant downward revision in the price target. This adjustment is primarily driven ...

Weeks after launching its first open call for diabetes advocates, Dexcom is spotlighting the resulting group of 16 people in ...

DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, today unveiled 16 new diabetes advocates to represent people living with diabetes globally as part of Dexcom’s World Diabetes Day ...

Looking back on patient monitoring stocks’ Q3 earnings, we examine this quarter’s best and worst performers, including DexCom ...

Dexcom has issued a Class I recall for its G6 Android app due to crashes that could cause users to miss critical glucose ...

Although DexCom stock has trailed the broader market over the past year, analysts remain bullish about its prospects.

However, the company's financial results have been pretty strong. And if DexCom can keep that up in its next quarterly update ...

SAN DIEGO--(BUSINESS WIRE)-- DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today that Stelo, the first over-the-counter ...

A software defect could cause the app to terminate, resulting in missed alerts or alarms. Dexcom required users to update the ...

Dexcom has been hit by a major safety issue for an Android version of its G6 continuous monitoring system app, leading the FDA to issue its most serious recall notice. | Dexcom has been hit by a major ...

Carrot’s Sprints members will have access to sleep, stress, activity and glucose data from Oura and Dexcom, along with ...